Skip to main content

Keyboard Shortcuts

Key Pair Function
Alt S Search Box
Alt T Top of Page
Alt H Home Page
Alt Index Button
Alt Next Button
Alt Prev Button
A4TE Logo

A4TE's Trans Health Project

Working for Transgender Equal Rights
Menu
  • Trans Health Insurance Tutorial
    • Choosing a Plan
    • Understanding Your Plan
    • Applying for Coverage
    • Understanding a Denial
    • Appealing a Denial
  • About Us
    • About A4TE's Trans Health Project
    • Privacy Policy
  • Contact Us
    • Contact A4TE
    • Contact A4TE's Trans Health Project
  • Resources
    • Legal Analysis
    • Medical Necessity Literature Reviews
    • Reporting Medical Provider Discrimination
    • Training Materials for Advocates
    • Provider Medical Necessity Letter Checklists
    • Health Insurance Medical Policies
    • Medical Organization Statements
    • State Health Insurance Laws and Guidance
    • Medicaid Regulations and Guidance
    • Gender Centers
    • Finding Trans Health Care Providers
    • State Employee Health Plans
    • Financial Aid for Transgender Surgeries
    • Gender Affirming Surgery Appeal Template
  • Tutorial del Seguro de Salud Trans
    • Cómo elegir un plan
    • Cómo entender su plan
    • Cómo solicitar cobertura
    • Cómo entender una denegación
    • Cómo apelar una denegación
Previous Page
Prev
Home
Home
Up
Up
Next Page
Next
  •  Home
  • Resources
  • Health Insurance Medical Policies
  • Current: Aetna - Gonadotropin-Releasing Hormone Analogs and Antagonists

Prev Index Gender Dysphoria/Reassignment [3 of 162] Next

Aetna

Gonadotropin-Releasing Hormone Analogs and Antagonists


Policy: Gonadotropin-Releasing Hormone Analogs and Antagonists
Policy Number: 0501
Last Update: 2023-07-14
Next Update: 2024-01-25

Youth Services:

Aetna considers Lupron Depot, Lupron Depot-PED, Leuprolide acetate (Eligard, Fensolvi), Goserelin (Zoladex), Vantas, Supprelin LA, and Triptorelin (Trelstar; Triptodur) medically necessary for the following indications: ... for pubertal suppression in preparation for gender reassignment in an adolescent member when all of the following criteria are met: 1. The member has a diagnosis of gender dysphoria; and 2. The member has reached Tanner stage 2 of puberty.

Back to top

Updated on Nov 27, 2023

Donate Now
Facebook Button Instagram Button
 Keyboard Shortcuts
 Privacy Policy
 A4TE Website

Copyright © 2024 Advocates For Trans Equality, Inc.  |  Tel: (202) 642-4542